Rozanolixizumab – November 2025

• Brand names:
  • Rystiggo®
• Pharmaceutical Company:
  • UCB AUSTRALIA PROPRIETARY LIMITED
• Condition/Indication: Generalised myasthenia gravis (gMG)
• Meeting Date: November 2025
• Public Summary Document (PSD) March 2025 - November 2025 PBAC Meetings - (PDF 949KB)
• Public Summary Document (PSD) March 2025 - November 2025 PBAC Meetings - (Word 443KB)

Related Public Summary Documents

• Rozanolixizumab – March 2025